Table 1.
Epidemiological and clinical data of patients with CR-KP and CS-KP isolates
| CR-KP | CS-KP | p-value | |
|---|---|---|---|
| N = 28 | N = 14 | ||
| Mean age (SD) | 62.93 (+/- 14.491) | 69.62 (+/- 16.717) | 0.186 |
| Male sex | 18 (64.3 %) | 7 (50 %) | 0.508 |
| Site of isolation | |||
| Urine | 10 (35.7 %) | 9 (64.3 %) | 0.107 |
| Blood culture | 6 (21.4 %) | 2 (14.3 %) | 0.697 |
| Surgical wound | 4 (14.3 %) | 1 (7.1 %) | 0.650 |
| Abdominal samples | 3 (10.7 %) | 0 | 0.539 |
| Respiratory samples | 4 (14.3 %) | 1 (7.1 %) | 0.643 |
| Others | 1 (3.6 %) | 1 (7.1 %) | 1 |
| Length of stay before acquisition (SD) | 28.43 (+/- 31.319) | 20.14 (+/- 31.705) | 0.430 |
| Overall mortality (related CR- or CS-KP)a | 35 % [7/20] | 11.11 % [1/9] | 0.371 (0.280) |
| (20 % [4/20]) | (0) | ||
| ICU acquisition | 9 (32.1 %) | 0 | 0.019* |
| Previous antibiotic therapy (treatment) | |||
| Penicillins/Betalactamase Inhibitor | 8 (28.6 %) | 2 (14.3 %) | 0.451 |
| Carbapenems | 14 (50 %) | 3 (21.4 %) | 0.102 |
| Third generation cephalosporins/Monobactams | 2 (7.1 %) | 1 (7.1 %) | 1 |
| Fluoroquinolones | 4 (14.3 %) | 3 (21.4 %) | 0.668 |
| Trimethoprim-sulfamethoxazole | 0 | 2 (14.3 %) | 0.106 |
| None | 0 | 3 (21.4 %) | 0.032* |
| Treatment | |||
| Penicillins/Betalactamase Inhibitor | 1 (3.6 %) | 0 | 1 |
| Carbapenems | 3 (10.7 %) | 7 (50 %) | 0.008* |
| Carbapenems + Amikacin | 1 (3.6 %) | 1 (7.1 %) | 1 |
| Tigecycline | 6 (21.4 %) | 1 (7.1 %) | 0.392 |
| Tigecycline + Amikacin | 1 (3.6 %) | 0 | 1 |
| Aminoglycosides | 1 (3.6 %) | 0 | 1 |
| Colistin | 4 (14.3 %) | 0 | 0.283 |
| Fosfomycin | 1 (3.6 %) | 0 | 1 |
| None | 1 (3.6 %) | 0 | 1 |
*p < 0.05 being considered significant
aPatients with non-significant isolation of CR-KP or CS-KP, considered colonized, were excluded from the mortality analysis